AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34351205 — intervention group
Group type: COMPARATOR
Intervention: Court-appointed expert testimony
Number of subjects: 93
Study 32443036 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme replacement therapy (PERT) with 2000 U lipase/kg/day in 4 doses plus hypercaloric enteral supplements
Number of subjects: 40
Study 32443036 — intervention group
Group type: COMPARATOR
Intervention: Control group received hypercaloric enteral supplements only
Number of subjects: 40
Study 35317771 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital storytelling method (n = 33)
Number of subjects: 60
Study 35317771 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (n = 33)
Number of subjects: 60
Study 34845204 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 0
Study 34845204 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical diabetes/weight management
Number of subjects: 0
Study 32251360 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa/benserazide 100/25 mg
Number of subjects: 63
Study 32251360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 34981829 — intervention group
Group type: EXPERIMENTAL
Intervention: Uptitration to Q2W from Q4W
Number of subjects: 331
Study 33972238 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amikacin and fosfomycin
Number of subjects: 0
Study 33972238 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard fosfomycin-amikacin neonatal regimen
Number of subjects: 0
Study 32319233 — intervention group
Group type: EXPERIMENTAL
Intervention: SCR followed by 6 cycles of platinum-based chemotherapy and niraparib maintenance
Number of subjects: 96
Study 32319233 — intervention group
Group type: COMPARATOR
Intervention: 6 cycles of platinum-based chemotherapy and niraparib maintenance alone
Number of subjects: 96
Study 36205312 — intervention group
Group type: EXPERIMENTAL
Intervention: Species‐Specific Bacterial Detector (SSBD)
Number of subjects: 77
Study 36205312 — intervention group
Group type: COMPARATOR
Intervention: Traditional cultivation method
Number of subjects: 77
Study 35194453 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + letrozole
Number of subjects: 90
Study 35194453 — intervention group
Group type: COMPARATOR
Intervention: MTX + placebo
Number of subjects: 90
Study 35695264 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM at 33°C
Number of subjects: 171
Study 35695264 — intervention group
Group type: COMPARATOR
Intervention: TTM at 36°C
Number of subjects: 171
Study 35695264 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated miR-9-3p levels at 48h
Number of subjects: 171
Study 35695264 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-9-3p
Number of subjects: 171
Study 35408245 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D VR task
Number of subjects: 0
Study 35408245 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D screen task
Number of subjects: 0
Study 35408245 — intervention group
Group type: COMPARATOR
Intervention: no task eyes open state
Number of subjects: 0
Study 32147084 — intervention group
Group type: EXPERIMENTAL
Intervention: Eurhythmy Therapy (EYT)
Number of subjects: 80
Study 32147084 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 80
Study 32989920 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib (200 mg once daily for 15 days)
Number of subjects: 24
Study 32989920 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel (150 μg)/Ethinyl Estradiol (30 μg) alone (reference)
Number of subjects: 24
Study 32079428 — intervention group
Group type: EXPERIMENTAL
Intervention: Shimian granules (SMG) 10.0 g orally 2 times daily for 1 month
Number of subjects: 53
Study 32079428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 36152871 — intervention group
Group type: EXPERIMENTAL
Intervention: mpMRI
Number of subjects: 640
Study 36152871 — intervention group
Group type: EXPERIMENTAL
Intervention: mpMRI PSAD
Number of subjects: 640
Study 36152871 — intervention group
Group type: COMPARATOR
Intervention: TRUS PSAD
Number of subjects: 640
Study 36152871 — intervention group
Group type: COMPARATOR
Intervention: TRUS
Number of subjects: 640
Study 33462851 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian adaptive design using a multiarmed bandit framework
Number of subjects: 0
Study 33462851 — intervention group
Group type: EXPERIMENTAL
Intervention: Thompson sampling for treatment allocation
Number of subjects: 0
Study 33462851 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical model for individual and population treatment effects
Number of subjects: 0
Study 32612355 — intervention group
Group type: EXPERIMENTAL
Intervention: WB‐EMS & Protein Supplement
Number of subjects: 100
Study 32612355 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 100
Study 32612355 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein Supplement
Number of subjects: 100
Study 32612355 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal prohormone of brain natriuretic peptide (NT-proBNP)
Number of subjects: 100
Study 34107708 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming acupuncture and moxibustion at temples combined with Deanxit
Number of subjects: 252
Study 34107708 — intervention group
Group type: COMPARATOR
Intervention: Routine group (control)
Number of subjects: 252
Study 32057570 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth (Danish strain 1331, Statens Serum Institut)
Number of subjects: 300
Study 32057570 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 300
Study 34774669 — intervention group
Group type: EXPERIMENTAL
Intervention: RS2-enriched wheat flour
Number of subjects: 30
Study 34774669 — intervention group
Group type: COMPARATOR
Intervention: wild-type flour
Number of subjects: 30
Study 34723652 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-activin A antibody
Number of subjects: 0
Study 34723652 — intervention group
Group type: COMPARATOR
Intervention: Elevated activin A, activin B, and FLRG at hospital admission
Number of subjects: 0
Study 36029208 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone therapy for 19 days
Number of subjects: 85
Study 36029208 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone therapy
Number of subjects: 85
Study 32960329 — intervention group
Group type: COMPARATOR
Intervention: cTACE (conventional transarterial chemoembolization)
Number of subjects: 50
Study 32960329 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM-TACE (drug-eluting beads transarterial chemoembolization)
Number of subjects: 50
Study 32960329 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM-TACE
Number of subjects: 50
Study 32960329 — intervention group
Group type: COMPARATOR
Intervention: cTACE
Number of subjects: 50
Study 33263237 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel wire fixation and BM injection at the fracture line
Number of subjects: 30
Study 33263237 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate fixation and BM injection at the fracture line
Number of subjects: 30
Study 33263237 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel bone wire fixation and placebo saline injection at the fracture line
Number of subjects: 30
Study 33263237 — intervention group
Group type: COMPARATOR
Intervention: Plate fixation and placebo injection at the fracture line
Number of subjects: 30
Study 34727202 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-enriched diet
Number of subjects: 51
Study 34727202 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 51
Study 33637625 — intervention group
Group type: EXPERIMENTAL
Intervention: PENG block
Number of subjects: 60
Study 33637625 — intervention group
Group type: COMPARATOR
Intervention: FNB
Number of subjects: 60
Study 35963959 — intervention group
Group type: COMPARATOR
Intervention: Ropanicant (SUVN-911) single doses (0.5, 6, 15, 30, and 60 mg) and multiple doses (15, 30, and 45 mg) administered orally for 14 days.
Number of subjects: 0
Study 35963959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropanicant (30 mg) administered orally in Study 2.
Number of subjects: 0
Study 35963959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropanicant (multiple doses) administered orally.
Number of subjects: 0
Study 35963959 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropanicant (various doses) administered orally.
Number of subjects: 0
Study 33681893 — intervention group
Group type: COMPARATOR
Intervention: TAC+MMF+PRED (cohort 1)
Number of subjects: 97
Study 33681893 — intervention group
Group type: EXPERIMENTAL
Intervention: EVL+MMF+PRED (cohort 2)
Number of subjects: 97
Study 33819495 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mg granisetron
Number of subjects: 0
Study 33819495 — intervention group
Group type: COMPARATOR
Intervention: 3-mg granisetron
Number of subjects: 0
Study 33833278 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial-body cryostimulation (PBC) - 3 minutes at -150 °C
Number of subjects: 18
Study 33833278 — intervention group
Group type: COMPARATOR
Intervention: Control condition - 3 minutes at room temperature (20 °C)
Number of subjects: 18
Study 36070920 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) using cilostazol
Number of subjects: 1878
Study 36070920 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (aspirin or clopidogrel alone)
Number of subjects: 1878
Study 33616815 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) for patients only (Arm 1)
Number of subjects: 510
Study 33616815 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) for patients and caregivers (Arm 2)
Number of subjects: 510
Study 33616815 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Arm 3)
Number of subjects: 510
Study 35777693 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure in addition to elective open-heart surgery
Number of subjects: 186
Study 35777693 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 186
Study 34350536 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended depth of focus (EDF) contact lenses
Number of subjects: 17
Study 34350536 — intervention group
Group type: COMPARATOR
Intervention: Single-vision (SV) contact lenses
Number of subjects: 17
Study 36400089 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine (0.5 ml intramuscularly once a year for up to 3 years)
Number of subjects: 5129
Study 36400089 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 5129
Study 32185143 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA extraction with classical mechanical and chemical cell disruption
Number of subjects: 0
Study 32185143 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA extraction with specific pre‐treatments
Number of subjects: 0
Study 32185143 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen storage for up to 1 year
Number of subjects: 0
Study 35999527 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA and DEX (12 mg) on day 1, no further DEX (DEX1)
Number of subjects: 0
Study 35999527 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA and DEX (12 mg) on day 1, oral DEX (4 mg daily) on days 2-3 (DEX3)
Number of subjects: 0
Study 35999527 — intervention group
Group type: COMPARATOR
Intervention: DEX (4 mg twice daily) on days 2-4 (DEX4; control)
Number of subjects: 0
Study 33964430 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) 1 g plus 100 mL saline
Number of subjects: 96
Study 33964430 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (100 mL saline)
Number of subjects: 96
Study 32470241 — intervention group
Group type: EXPERIMENTAL
Intervention: RF powered toothbrush
Number of subjects: 85
Study 32470241 — intervention group
Group type: COMPARATOR
Intervention: Control powered toothbrush
Number of subjects: 85
Study 35450161 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate walking thrice weekly (MOD × 3/week)
Number of subjects: 0
Study 35450161 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous walking thrice weekly (VIG × 3/week)
Number of subjects: 0
Study 35450161 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate walking once weekly (MOD × 1/week)
Number of subjects: 0
Study 35450161 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous walking once weekly (VIG × 1/week)
Number of subjects: 0
Study 35450161 — intervention group
Group type: COMPARATOR
Intervention: Attention control (CON)
Number of subjects: 0
Study 33594600 — intervention group
Group type: EXPERIMENTAL
Intervention: Strains BR 10788 and BR 11793
Number of subjects: 877
Study 33594600 — intervention group
Group type: EXPERIMENTAL
Intervention: Strains with antagonistic effects
Number of subjects: 877
Study 36030400 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose quadrivalent inactivated vaccine before hospital discharge
Number of subjects: 1801
Study 36030400 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose quadrivalent inactivated vaccine administered in the outpatient setting 30 days after randomization
Number of subjects: 1801
Study 33848441 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrating Mesh Nebulizer (VMN) with salbutamol (2.5 mg)
Number of subjects: 30
Study 33848441 — intervention group
Group type: COMPARATOR
Intervention: Jet Nebulizer (JN) with salbutamol (2.5 mg)
Number of subjects: 30
Study 33064669 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 180
Study 33064669 — intervention group
Group type: EXPERIMENTAL
Intervention: Etamsylate
Number of subjects: 180
Study 33064669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 32023524 — intervention group
Group type: EXPERIMENTAL
Intervention: smartphone mobile app
Number of subjects: 181
Study 32023524 — intervention group
Group type: COMPARATOR
Intervention: standard care
Number of subjects: 181
Study 35666933 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors of sex trafficking (ST)
Number of subjects: 1264
Study 35666933 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1264
Study 35666933 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 1264
Study 35666933 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment
Number of subjects: 1264
Study 35666933 — intervention group
Group type: EXPERIMENTAL
Intervention: Better social relationships
Number of subjects: 1264
Study 35028158 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical collar
Number of subjects: 0
Study 35028158 — intervention group
Group type: COMPARATOR
Intervention: No collar
Number of subjects: 0
Study 32273696 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng capsules (200 mg, twice per day)
Number of subjects: 200
Study 32273696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 36175099 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer peer health and well-being coaching
Number of subjects: 0
Study 36175099 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33751924 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 53
Study 33751924 — intervention group
Group type: COMPARATOR
Intervention: Placebo-PBMT
Number of subjects: 53
Study 35088549 — intervention group
Group type: EXPERIMENTAL
Intervention: WMEN diet
Number of subjects: 50
Study 35088549 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% calorie-reduced diet
Number of subjects: 50
Study 35088549 — intervention group
Group type: COMPARATOR
Intervention: Food insecurity
Number of subjects: 50
Study 33563735 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia lidocaine hydrochloride 2% in group A
Number of subjects: 60
Study 33563735 — intervention group
Group type: COMPARATOR
Intervention: Systemic analgesia intravenous tramadol chloride 100 mg in group B
Number of subjects: 60
Study 32711689 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief lay counsellor-delivered, problem-solving intervention
Number of subjects: 0
Study 32711689 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34879374 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DES)
Number of subjects: 6251
Study 34879374 — intervention group
Group type: COMPARATOR
Intervention: Bare-Metal Stents (BMS)
Number of subjects: 6251
Study 34879374 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 6251
Study 32219442 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax plus LDAC
Number of subjects: 211
Study 32219442 — intervention group
Group type: COMPARATOR
Intervention: LDAC alone
Number of subjects: 211
Study 35201540 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement into the homes of trained, supported foster parents
Number of subjects: 0
Study 35201540 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch‐up intervention
Number of subjects: 0
Study 35201540 — intervention group
Group type: COMPARATOR
Intervention: Orphanage care
Number of subjects: 0
Study 34433679 — intervention group
Group type: EXPERIMENTAL
Intervention: EDSS
Number of subjects: 1008
Study 34433679 — intervention group
Group type: EXPERIMENTAL
Intervention: T25FW
Number of subjects: 1008
Study 34433679 — intervention group
Group type: EXPERIMENTAL
Intervention: NHPT
Number of subjects: 1008
Study 34433679 — intervention group
Group type: COMPARATOR
Intervention: Kaplan-Meier method
Number of subjects: 1008
Study 32740183 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal nutrition curriculum (delivered in 95% of programs, 19/20)
Number of subjects: 95
Study 32740183 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported fellow comfort with nutrition topics
Number of subjects: 95
Study 32740183 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsibility for writing daily parenteral nutrition prescriptions
Number of subjects: 95
Study 32740183 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort in providing parenteral nutrition support
Number of subjects: 95
Study 32740183 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived effectiveness of nutritional curriculum
Number of subjects: 95
Study 32212483 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (1g, tid) for 3 months
Number of subjects: 240
Study 32212483 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E (100 mg, tid) for 3 months (Control)
Number of subjects: 240
Study 616683729 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing intervention (details not specified)
Number of subjects: 48
Study 616683729 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 48
Study 36285019 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual procedures for recruitment and management of clinical trial participants
Number of subjects: 0
Study 36285019 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual procedures for obtaining informed consent and measurements
Number of subjects: 0
Study 36285019 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual procedures during the COVID-19 pandemic
Number of subjects: 0
Study 34774221 — intervention group
Group type: EXPERIMENTAL
Intervention: KRd plus ASCT
Number of subjects: 474
Study 34774221 — intervention group
Group type: COMPARATOR
Intervention: KCd plus ASCT
Number of subjects: 474
Study 34774221 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib plus lenalidomide (maintenance)
Number of subjects: 474
Study 34774221 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide alone (maintenance)
Number of subjects: 474
Study 33745147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBT-I)
Number of subjects: 56
Study 33745147 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene control
Number of subjects: 56
Study 32770558 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE)
Number of subjects: 0
Study 32770558 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose steroid regimen
Number of subjects: 0
Study 32770558 — intervention group
Group type: COMPARATOR
Intervention: No TPE
Number of subjects: 0
Study 32569128 — intervention group
Group type: EXPERIMENTAL
Intervention: External focus training
Number of subjects: 66
Study 32569128 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal focus training
Number of subjects: 66
Study 32569128 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 32674036 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred medication self-management support programme conducted by trained nurses
Number of subjects: 155
Study 32674036 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 155
Study 32701926 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg methylprednisolone
Number of subjects: 52
Study 32701926 — intervention group
Group type: EXPERIMENTAL
Intervention: 30mg methylprednisolone
Number of subjects: 52
Study 32701926 — intervention group
Group type: EXPERIMENTAL
Intervention: 40mg methylprednisolone
Number of subjects: 52
Study 32701926 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (placebo)
Number of subjects: 52
Study 35209939 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids for 8 weeks
Number of subjects: 120
Study 35209939 — intervention group
Group type: COMPARATOR
Intervention: placebo for 8 weeks
Number of subjects: 120
Study 32116248 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning Therapy (LT), a combination of cognitive training and stimulation.
Number of subjects: 0
Study 32116248 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study 35630024 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 mg/kg every three weeks up to 17 cycles) combined with carboplatin (AUC 6) and paclitaxel (175 mg/m2 for the first six cycles)
Number of subjects: 35
Study 34231178 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast stimulation
Number of subjects: 87
Study 34231178 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical balloon
Number of subjects: 87
Study 34231178 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous labor (control)
Number of subjects: 87